3D 스캐폴드 시장 : 규모, 점유율, 동향 분석, 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

3D Scaffolds Market Size, Share & Trends Analysis Report By Type, By Application (Tissue Engineering & Regenerative Medicine, Stem Cell Research), By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,876,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,368,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,351,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

3D 스캐폴드 시장 요약

세계 3D 스캐폴드 시장 규모는 2024년 9억 950만 달러로 평가되었으며, 2033년까지 20억 860만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 9.53%로 성장할 전망입니다. 이러한 성장은 첨단 세포 배양 및 조직 엔지니어링 솔루션에 대한 수요가 증가함에 따라 견인되었습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 3D 스캐폴드 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 3D 스캐폴드 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 3D 스캐폴드 시장 : 유형별 추정·동향 분석

• 부문 대시보드
• 세계의 3D 스캐폴드 시장 변동 분석
• 세계의 3D 스캐폴드 시장 규모와 동향 분석(유형별, 2021-2033년)
• 천연
• 합성
• 복합

제5장 3D 스캐폴드 시장 : 용도별 추정·동향 분석

• 부문 대시보드
• 세계의 3D 스캐폴드 시장의 용도 변동 분석
• 세계의 3D 스캐폴드 시장 규모와 동향 분석(용도별, 2021-2033년)
• 조직 공학 및 재생 의료
• 줄기세포 연구
• 암 조사
• 약물 발견과 독성 스크리닝
• 기타

제6장 3D 스캐폴드 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 세계의 3D 스캐폴드 시장의 최종 용도 변동 분석
• 세계의 3D 스캐폴드 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
• 생명공학 및 제약조직
• 연구실 및 기관
• 병원과 진단센터
• 기타

제7장 3D 스캐폴드 시장 : 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2033년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2021-2033년:
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁의 분류
• 전략 매핑
• 기업시장 포지셔닝 분석, 2024년
• 기업 프로파일
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • CellSystems
  • Femtika
  • Gelatex Technologies
  • ReproCELL Inc.
  • Ilex Life Sciences
  • BellaSeno GmbH
  • Ossiform

SHW

영문 목차

영문목차

3D Scaffolds Market Summary

The global 3D scaffolds market size was valued at USD 909.5 million in 2024 and is projected to reach USD 2,008.6 million by 2033, growing at a CAGR of 9.53% from 2025 to 2033. This growth is driven by the rising demand for advanced cell culture and tissue engineering solutions.

Global 3D Scaffolds Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global 3D scaffolds market on the basis of type, application, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Natural
• Synthetic
• Composite
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Tissue Engineering & Regenerative Medicine
• Stem Cell Research
• Cancer Research
• Drug Discovery & Toxicology Screening
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biotechnology and Pharmaceutical Organizations
• Research Laboratories and Institutes
• Hospitals and Diagnostic Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information Analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. 3D Scaffolds Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing demand for organ transplantation & tissue engineering
    • 3.2.1.2. Rise in investments and R&D funding for cell-based research
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with implementation
• 3.3. 3D Scaffolds Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. 3D Scaffolds Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global 3D Scaffolds Market Type Movement Analysis
• 4.3. Global 3D Scaffolds Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Natural
  • 4.4.1. Natural market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Synthetic
  • 4.5.1. Synthetic market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Composite
  • 4.6.1. Composite market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. 3D Scaffolds Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global 3D Scaffolds Market Application Movement Analysis
• 5.3. Global 3D Scaffolds Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Tissue Engineering & Regenerative Medicine
  • 5.4.1. Tissue engineering & regenerative medicine market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Stem Cell Research
  • 5.5.1. Stem cell research market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Cancer Research
  • 5.6.1. Cancer research market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Drug Discovery & Toxicology Screening
  • 5.7.1. Drug discovery & toxicology screening market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. 3D Scaffolds Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global 3D Scaffolds Market End Use Movement Analysis
• 6.3. Global 3D Scaffolds Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Biotechnology and Pharmaceutical Organizations
  • 6.4.1. Biotechnology and pharmaceutical organizations market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Research Laboratories and Institutes
  • 6.5.1. Research laboratories and institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Hospitals and Diagnostic Centers
  • 6.6.1. Hospitals and diagnostic centers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. 3D Scaffolds Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Competitive scenario
    • 7.4.1.3. Regulatory framework
    • 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Merck KGaA
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Thermo Fisher Scientific Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. CellSystems
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Femtika
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Gelatex Technologies
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. ReproCELL Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Ilex Life Sciences
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. BellaSeno GmbH
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Ossiform
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives

관련자료